You are here

  • Home
  • Archive
  • Volume 2, Issue 1
  • Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome

Article info

Article menu

Download PDFPDF

Research Article
Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome

Authors

  • Mizuki Nishino Department of RadiologyBrigham and Women’s Hospital and Dana-Farber Cancer Institute 450 Brookline Avenue 02215 Boston MA USA PubMed articlesGoogle scholar articles
  • Anita Giobbie-Hurder Department of Biostatistics and Computational BiologyDana-Farber Cancer Institute 450 Brookline Avenue 02215 Boston MA USA PubMed articlesGoogle scholar articles
  • Nikhil H Ramaiya Department of RadiologyBrigham and Women’s Hospital and Dana-Farber Cancer Institute 450 Brookline Avenue 02215 Boston MA USA PubMed articlesGoogle scholar articles
  • F Stephen Hodi Department of Medical Oncology and Department of MedicineDana-Farber Cancer Institute and Brigham and Women’s Hospital 450 Brookline Avenue 02215 Boston MA USA PubMed articlesGoogle scholar articles
  1. ↵a Mizuki_Nishino{at}DFCI.HARVARD.EDU
  2. ↵b agiohur{at}jimmy.harvard.edu
  3. ↵c NR988{at}partners.org
  4. ↵d Stephen_Hodi{at}dfci.harvard.edu
View Full Text

Citation

Nishino M, Giobbie-Hurder A, Ramaiya NH, et al
Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome
Journal for ImmunoTherapy of Cancer 2014;2:40. doi: 10.1186/s40425-014-0040-2

Publication history

  • Received September 15, 2014
  • Accepted October 28, 2014
  • First published November 18, 2014.
Online issue publication 
November 18, 2014

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.